Bausch Health (BHC)
(Delayed Data from NYSE)
$5.63 USD
-0.47 (-7.70%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $5.62 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BHC 5.63 -0.47(-7.70%)
Will BHC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BHC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHC
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
BHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Other News for BHC
Bausch Health Companies (BHC) Gets a Hold from Truist Financial
RBC Capital Remains a Hold on Bausch Health Companies (BHC)
Bausch Health: A Balanced Hold Amid Revenue Growth and Operational Challenges
Piper downgrades Bausch Health to Underweight with solvency 'top of mind'
Bausch Health Companies: Sell Rating Reiterated Amid Spin-Off Uncertainties and Financial Concerns